Home › The Medicines Company And Alnylam Form Strategic Alliance To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 For The Treatment Of Hypercholesterolemia
 

Keywords :   


The Medicines Company And Alnylam Form Strategic Alliance To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 For The Treatment Of Hypercholesterolemia

2013-02-04 07:00:00| drugdiscoveryonline News Articles

The Medicines Company and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced recently that they have formed an exclusive global alliance for the development and commercialization of Alnylam’s ALN-PCS RNAi therapeutic program for the treatment of hypercholesterolemia

Tags: the of form company

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.11Tropical Storm Lane Graphics
02.11Subtropical Storm Patty Graphics
02.11Tropical Storm Lane Forecast Discussion Number 4
02.11Subtropical Storm Patty Wind Speed Probabilities Number 2
02.11Summary for Tropical Storm Lane (EP3/EP132024)
02.11Subtropical Storm Patty Public Advisory Number 2
02.11Subtropical Storm Patty Forecast Advisory Number 2
02.11Subtropical Storm Patty Update Statement
More »